The aim of the study was to analyze the impact of minimal residual disease (MRD) after reinduction therapy on the outcome of children with relapsed 'high-risk' acute lymphoblastic leukemia (ALL). Sixty patients with isolated or combined marrow relapse were studied. All patients belonged to the S3 or S4 groups, as defined by the Berlin-Frankfurt-Mü nster stratification for relapsed ALL. MRD was studied by real-time quantitative PCR after the first, second and third chemotherapy course (time points 1 (TP1), 2 (TP2) and 3 (TP3), respectively). MRD results, not used for treatment refinement, were categorized as negative (NEG MRD), positive not-quantifiable (POS-NQ MRD) when MRD level was below quantitative range (a level o10
Introduction
The treatment of acute lymphoblastic leukemia (ALL) in children has improved over the recent decades, and nowadays nearly 80% of patients can be cured with chemotherapy. 1 Nevertheless, disease recurrence remains the leading cause of treatment failure.
While a substantial proportion of children with relapsed ALL achieve a second remission, the overall final outcome remains unsatisfactory. [2] [3] [4] [5] [6] [7] A number of studies analyzed factors that influence the outcome of relapsed ALL. The Berlin-Frankfurt-Mü nster (BFM) ALL Relapse Study Group identified, as poor prognostic factors after first relapse, a short duration of first remission, an isolated bone marrow (BM) relapse and T-cell immunophenotype. 2 Further studies have confirmed these observations. 3, 4, 8, 9 In view of these results, the most recent protocols for relapsed ALL are based on patient stratification according to these risk factors.
However, relapsed patients belonging to the higher risk groups (those with an early BM recurrence or with T-ALL marrow relapse) have a low probability of event-free survival (EFS), in particular when treated with chemotherapy alone. 6 Minimal residual disease (MRD) has already proven to be an important prognostic factor for a better stratification of patients in different risk classes in first-line treatment protocols. 10, 11 The feasibility of measuring MRD for patients' stratification has been recently reported also in a large cohort of children with ALL. 12 Retrospective studies performed on stored samples have suggested that MRD could be of relevant importance also in intermediate-risk relapsed patients in second remission. 13, 14 The aim of this study was to prospectively evaluate whether the early quantization of molecular response to treatment in children with relapsed ALL could also be used to predict the outcome of patients with poor prognostic characteristics.
Materials and methods

Patients
The study included 60 consecutive pediatric patients with a diagnosis of ALL, who experienced a BM or combined (BM plus an extramedullary site) relapse between June 2003 and December 2006, after first-line chemotherapy treatment according to the AIEOP ALL 2000 protocol. All patients belonged to either S3 or S4 risk group, as defined by the BFM risk group stratification for relapsed ALL. 2 Patients' characteristics are summarized in Table 1 .
Diagnosis of ALL was made according to standard criteria. An isolated BM relapse was diagnosed with X25% lymphoblasts among nucleated BM cells, without evidence of extramedullary relapse. In patients with proven extramedullary relapse, a combined relapse was diagnosed when the percentage of lymphoblasts in BM was greater than 5%.
Relapses occurring within 18 months from the start of the treatment were defined as very early, whereas relapses occurring after 18 months from the start of treatment but within 6 months after discontinuation of frontline treatment were defined as early. All patients enrolled presented with a BM or combined, early or very early, relapse.
The S3 group included children with B-cell precursor ALL early BM relapse, whereas the S4 group comprised children with B-cell precursor ALL experiencing very early BM or combined relapse and those with T-cell ALL BM relapse, irrespective of the time between diagnosis and relapse. 2 The inclusion of patients in this study was based exclusively on the following: (i) the attribution to the S3 or S4 risk group; (ii) the achievement of a second hematological and morphological complete remission (CR); (iii) the availability of BM samples at relapse and at one or more subsequent time points, namely time points 1 (TP1), 2 (TP2) and 3 (TP3), that is, after 3-5 weeks (after the first reinduction cycle), 6-8 weeks (after the second chemotherapy cycle) and 9-16 weeks (after the third chemotherapy cycle) from the beginning of the relapse protocol.
Ten patients who relapsed during the period of study accrual but with no informative molecular marker (5 patients) or with a molecular marker that did not reach the required level of sensitivity of 10 À4 (5 patients) were excluded from the study. Written informed consent was obtained from the patients and/or their guardians, and the study was approved by the Institutional Review Boards of the participating centers.
Treatment protocol
All patients received reinduction chemotherapy as planned in the AIEOP ALL REC 2003 protocol for S3 and S4 groups. Briefly, children were randomized to receive either a 5-day first induction course with fludarabine (30 Owing to the severity of the prognosis for S3 and S4 patients, after induction and consolidation, all children had the indication to receive allogeneic hematopoietic stem cell transplantation (HSCT), this choice being supported by data from Borgmann et al. 7 The majority of treating centers performed transplants from matched family or unrelated donors, whereas transplants from HLA-partially matched (that is, haploidentical) family donors were performed only in a limited number of institutions with a specific program on haploidentical T-celldepleted HSCT. For this reason, some children lacking a matched family or unrelated donor did not receive any form of allogeneic HSCT. In detail, 33 patients received allogeneic HSCT, 4 from HLA-matched family donor, 21 from compatible unrelated volunteer and 8 from HLA-haploidentical family donor. Patients who did not undergo allogeneic HSCT received maintenance chemotherapy according to the AIEOP ALL REC 2003 protocol.
Minimal residual disease results were not available to the treating physician and did not influence treatment decisions.
MRD analysis
DNA of BM mononuclear cells, obtained after Ficoll-Paque centrifugation, was extracted and purified using Gentra kit (Gentra System, Minneapolis, MN, USA). PCR analysis to detect specific TCRg, TCRd, and VDJH, DJH, VK and IRSS gene rearrangements was performed at diagnosis and again at the time of relapse using methods published elsewhere. [15] [16] [17] Clonal gene rearrangements, identified by homo/heteroduplex analysis, were sequenced by dye-terminator cycle sequencing kit on ABI Prism 310 (Applied Biosystems, Foster City, CA, USA). 18 MRD levels in follow-up samples were analyzed by real-time quantitative PCR with hydrolysis (TaqMan) probes. [19] [20] [21] [22] We used at least one molecular marker identified at the time of relapse. In detail, at relapse, all patients of this cohort conserved at least one of the original gene rearrangements. Only markers with a cutoff level of at least 10 À4 were considered. In patients with more than one marker available, if MRD levels differed between the two markers, the highest MRD level was chosen for final MRD assessment. The real-time PCR analysis of BM samples was performed in accordance with the guidelines published by the European Study Group on MRD detection in ALL. 23 Minimal residual disease negativity was established when there was absence of specific amplification or amplification within 1 threshold cycle (Ct) of the background or amplification with a distance of more than 20 Ct's (DCt) from the undiluted diagnostic sample. A follow-up sample was considered as MRD positive if it showed a specific amplification product of more than 1 Ct lower than the background and separated less than 20 Ct's (DCt) from the undiluted diagnostic sample. MRD values were given if the sample gave a Ct within the QR of the PCR and the DCt between replicates was less than 1.5. 
Statistical analysis
Statistical analysis used 1 January 2008, as reference date.
Overall survival and EFS were calculated by the KaplanMeier method; comparisons between group were performed with the log-rank test. 24 Relapse incidence (RI) and treatmentrelated mortality (TRM) were calculated as cumulative incidence curves. [25] [26] [27] Overall survival, EFS, RI and TRM were estimated from the date of first relapse to the date of analysis or to the date of an adverse event. All results were expressed as 3-year probability or 3-year cumulative incidence (%) and 95% confidence interval (95% CI).
A univariate analysis of EFS, RI and TRM was performed for the whole study population. For multivariate analyses, the Cox proportional hazard regression model was used.
28,29 w 2 test was used to compare differences in percentages.
All P-values are two-sided and values less than 0.05 were considered to be statistically significant. The SAS package (SAS Institute, Cary, NC, USA) and NCSS 2001 (Number Cruncher Statistical Systems, Kaysville, UT, USA) were used for analysis of the data.
Results
No statistical difference, in terms of presenting features or clinical outcome, was observed between the 60 patients analyzed and the 10 patients who relapsed during the study period but who were excluded due to lack of an informative marker (data not shown). For this reason, only the results of the analysis on the 60 patients fulfilling the inclusion criteria are presented.
Overall outcome
Median observation time for surviving patients is 15 months (range, 4-48 months).
All 60 patients achieved a second morphological remission after the first induction course, this being one of the inclusion criteria. Overall, 27 of the 60 patients (45%) are alive: 26 (43%) are in second CR, whereas 1 child is alive after a subsequent BM relapse (2%). The estimated 3-year overall survival probability is 32% (95% CI, 16-47), whereas the 3-year EFS probability is 27% (95% CI, 8-45) (Figure 1a) .
Twenty-six patients (43%) had a second leukemia relapse, at a median of 5 months after the first one (range, 1-31 months). The 3-year cumulative RI is 59% (95% CI, 42-81) (Figure 1b) .
Eight patients (13%) died in second CR due to treatmentrelated causes, at a median of 115 days after the first relapse (range, 55-259). The estimated 3-year cumulative incidence of TRM is 15% (95% CI, (Figure 1b) .
MRD evaluation
On the whole, 119 MRD analyses were performed on the 60 patients studied, using 70 markers that had already been identified at diagnosis and 21 at relapse. MRD was evaluated at TP1 in 45 cases (75%), at TP2 in 28 cases (47%) and at TP3 in 46 cases (77%). Only 11 patients (18%) had only one time point analyzed, 10 (17%) had all the three estimations and 39 (65%) had two time points evaluated.
As summarized in Table 2 , 56% of the tests at TP1 were POS, 24% were POS-NQ and 20% were NEG. At TP3, 48% of the tests were still POS, 22% were POS-NQ and only 30% were NEG (P ¼ NS comparing TP1 vs TP3 results). In particular, considering only the 49 patients with at least two time points studied, we can observe that:
(i) all the nine children already NEG at TP1 remained NEG at the subsequent time points; (ii) of the 12 patients with a first POS-NQ result, 5 (42%) became negative at a subsequent control, 5 (42%) remained POS-NQ, whereas only 2 (16%) presented a subsequent worse result, becoming POS; (iii) considering the 28 patients with a first POS result, only 1 (4%) improved to NEG, 6 cases (21%) partially improved to POS-NQ, whereas in the remaining 21 patients (75%), MRD remained POS also at the following controls. A NEG or a POS-NQ MRD result was associated with a better outcome. Fourteen of the 17 patients who had at least one NEG MRD result at any time point (82%) are alive and in remission (the remaining three died in remission due to treatment-related complications), and 8 of the 15 children with at least a POS-NQ result at any time point (53%) are alive and disease free. On the contrary, only 4 out of the 28 patients with all POS MRD results (14%), including children with a single evaluation, are alive and disease free (Po0.001).
The influence of MRD result on EFS is shown in Figure 2 . The 3-year EFS was 79% (95% CI, 52-100) for patients with a NEG MRD result at first time point analyzed, 43% (95% CI, 4-82) for those with a POS-NQ MRD and 18% (95% CI, 4-32) for children with POS MRD at first time point analyzed (P ¼ 0.005). When available, TP1 was also already predictive of the probability of EFS in univariate analysis. In fact, EFS was 73% (95% CI, 41-100), 45% (95% CI, 4-87) and 19% (95% CI, 3-35) for patients with NEG, POS-NQ and POS result at TP1, respectively (Po0.05).
The effect of MRD on patients' EFS was due to a significantly different risk of relapse among the three MRD groups. In fact, considering TP1, RI was 0%, 43% (95% CI, 17-100) and 73% (95% CI, 57-94) for NEG, POS-NQ and POS patients, respectively (P ¼ 0.003). Furthermore, considering the first time point available, RI was 0%, 48% (95% CI, 21-100) and 67% (95% CI, 53-86) for NEG, POS-NQ and POS patients, respectively (P ¼ 0.0019). On the contrary, none of the MRD time points was associated with differences in TRM (data not shown).
As shown above, only 12 out of the 40 patients with multiple MRD analyses improved their result from POS-NQ to NEG or from POS to POS-NQ or NEG (the remaining 9 cases with multiple analyses were already negative at the first control). EFS of the 12 cases with improving MRD was significantly better than that of patients with stable MRD positivity: 67% (95% CI, 35-98) vs 12% (95% CI, 0-26); Po0.01.
Finally, when a separate analysis for patients who received or did not receive HSCT was performed, the effect of MRD on outcome was similar to that observed on the whole study population, even though the lower number of patients within each subgroup decreased the power of the statistical tests. For the HSCT group, EFS was 86, 44 and 26%, respectively, for patients NEG, POS-NQ and POS at first time point available (P ¼ 0.09), whereas in children who did not receive HSCT, EFS was 67, 50 and 9%, respectively, for patients NEG, POS-NQ and POS at first time point available (P ¼ NS).
The predictive value of MRD on clinical outcome was also confirmed by the multivariate analysis (see Table 4 ). The relative risk of treatment failure for patients POS at the first time point available vs NEG patients was 4.40 (95% CI, 1.01-19.33; Po0.05). On the contrary, the relative risk of treatment failure for the POS-NQ group vs the NEG group was not statistically significant (RR ¼ 2.04; 95% CI, 0.39-10.59; P ¼ NS). The only other factors associated with an increased risk of treatment failure in multivariate analysis were BFM classification (relative risk for S4 vs S3 patients ¼ 2.87 (95% CI, 1.31-6.30; Po0.01)) and allogeneic HSCT (relative risk for patients given HSCT vs patient not given HSCT ¼ 0.28 (95% CI, 0.13-0.59; Po0.005)).
Discussion
Despite the advances in the treatment of childhood ALL, approximately 20-25% of children suffer leukemia relapse. [30] [31] [32] [33] The present salvage protocols offer a probability of second CR between 70 and 95%, but reported cure rates after a first relapse are between 30 and 40%. 3, 4, 34 In particular, for patients of the subgroups with poorer prognosis, the reported cure rate is about 20% if allogeneic HSCT is employed and below 5% for children not transplanted. 2, 6 In all published studies, the most frequent adverse event was a further BM relapse.
In our cohort, the 3-year EFS was 27% and a second relapse was the most frequent adverse event. For this reason, a major task of future clinical trials will be to predict more precisely the occurrence of relapses, thus identifying patients with the indication to alternative therapies aimed at reducing the tumor burden before an allograft.
Minimal residual disease is a powerful parameter for the prediction of relapse in patients with ALL receiving first-line chemotherapy. 10, [35] [36] [37] Nevertheless, only very few studies on a limited number of patients studied MRD and its prognostic value Table 2 Results of MRD analysis : patients with MRD level X10
À4
. POS-NQ: patients with positive MRD result, even though at a level o10
, very near to the sensitivity threshold of the technique and not precisely quantifiable. NEG: patients with completely negative MRD analysis results. NS: non-significant. Time point 1: after the first chemotherapy cycle (after 3-5 weeks from relapse). Time point 2: after the second chemotherapy cycle (6-8 weeks from relapse). Time point 3: after the third chemotherapy course (9-16 weeks from relapse). First time point available: the first time point available for each single patient, irrespective of the number of chemotherapy cycles administered. Last time point available: the last time point available for each single patient, irrespective of the number of chemotherapy cycles administered.
MRD in relapsed, high-risk, childhood ALL M Paganin et al during second-line chemotherapy for relapsed ALL. 14, 38 In the retrospective study by Eckert et al., 14 only patients belonging to the intermediate prognosis group (S2, according to the BFM risk group stratification) were evaluated, whereas the study published by Coustan-Smith et al. 38 also included high-risk patients, but employed a different methodology, based on flow , very near to the sensitivity threshold of the technique and not precisely quantifiable. NEG: patients with completely negative MRD analysis results.
MRD in relapsed, high-risk, childhood ALL M Paganin et al cytometry. However, both studies suggested that MRD analysis could predict long-term outcome in relapsed childhood ALL and could be used to guide the choice of post-remission treatment.
In our hands, MRD measurement using PCR in high-risk relapsed ALL permitted the differentiation of patients with a high risk of relapse from those with a good probability of cure. EFS was more than 70% for patients with NEG MRD, about 40% for those with POS-NQ results and about 20-30% for children with POS MRD. Furthermore, MRD analysis discriminated between good and poor prognosis patients already at TP1, after only one cycle of chemotherapy. In fact, considering only TP1 results, the 3-year EFS was 73, 45 and 19% for NEG, POS-NQ and POS patients, respectively (Po0.05).
When a separate analysis for patients who received or did not receive HSCT was carried out, the prognostic impact of MRD on outcome was observed in both subgroups of patients. This observation is also in agreement with previously published studies pointing out the predictive function of MDR assessed immediately before allogeneic HSCT. [39] [40] [41] Another important finding was that, at least with the chemotherapy adopted in our protocol, only a minority of patients with POS MRD at TP1 improved their MRD status with a second or third chemotherapy course. In fact, we observed only an 8% decrease in the percentage of POS patients from TP1 to TP3 (56 vs 48%, respectively, P ¼ NS), and analyzing 49 MRD in relapsed, high-risk, childhood ALL M Paganin et al patients with two or more time points available, only one child (4%) with a POS first result achieved a NEG result at a subsequent TP analysis, and only six children (21%) improved from POS to POS-NQ. The importance of a POS result at the first MRD evaluation was confirmed in multivariate analysis, the S4 group of BFM classification being the only other additional factor associated with a worse outcome.
Even though the observation time for our population is relatively short (the median follow-up time is 15 months), it must be considered that only patients belonging to the highest risk groups were enrolled, and that all of them experienced a very early (48%) or early (52%) first leukemia recurrence. Moreover, for relapsing patients, the time from first to second leukemia relapse was very short, the median interval being only 5 months. For this reason, it is reasonable to expect only a very low number of further relapses, even with a longer follow-up.
In conclusion, our study shows that MRD analysis by PCR is a feasible and promising approach to stratify patients also in protocols for relapsed, high-risk ALL. MRD evaluation was able to identify patients who could benefit from the treatment and with a probability of cure of about 70%. On the other hand, a POS first MRD result identified, after just one chemotherapy cycle, a subset of patients who seem not to benefit from further consolidations, including allogeneic HSCT. These patients with extremely severe prognosis could have the indication to experimental treatment strategies on the basis of the use of novel antileukemia agents, such as clofarabine, 42 nelarabine 43 or anti-CD22 monoclonal antibodies, 44 aimed at obtaining a better leukemia control before allogeneic HSCT.
